Judge he grants in demand for discrimination against DACA beneficiaries

A federal judge granted the final approval of a collective claim agreement between First Tech Credit Union and the beneficiaries of the deferred action for children in childhood (DACA) and other immigrants who were denied the total consideration for credit due to their immigration status. Obama introduced the DACA program in 2012, alleging the inaction of Congress on legislation aimed at offering a way to legal status to those brought to the country when they were children. There were legal battles, including two reviews of the Supreme Court. Despite this, over the years, this program has suffered different challenges and one of them were the policies of financial institutions that allegedly discriminate against DACA beneficiaries and other immigrants. Trump already tried to end Daca in his first term.Credit: Mark Schiefelbein | AP Therefore, the Maldef Organization (Mexico-American Educational Fund and Legal Defense) represented the beneficiaries of DACA and other immigrants who formed the group of the agreement reached with financial institutions after being demanded for denying services to the beneficiaries of DACA and other immigrants depending on its immigration status. As reported, Since 2017, Maldef has submitted 19 demands that challenge the policies of financial institutions that allegedly discriminate against DACA beneficiaries and other immigrants. “Regardless of biased rhetoric emanating from the new administration, the law protects immigrants from discrimination,” said Thomas A. Saenz, president and general advisor of Maldef. “When a credit cooperative like First Tech acknowledges that immigrants must access critical financial products, our economy and society improve.” As part of the agreement, First Tech created a compensation fund of $ 81,500 to compensate for the kind of immigrants affected by the questioned practice. The agreement, which received preliminary approval in October, also includes a change in the First Tech policy. “Daca’s beneficiaries throughout the country play an important role in the progress of our nation,” said Eduardo Casas, a maldef lawyer. Maldef filed the lawsuit in 2023 on behalf of Ismael Rodríguez Pérez, Daca beneficiary. Pérez was initially approved a credit line with mortgage guarantee (Heloc), but then he learned that the loan was denied because he was not permanent resident. The lawyers argued that the First Tech policy violated section 1981 of the Federal Civil Rights Law of 1866 and the UNRUH Civil Rights Law of California, which prohibit discrimination in certain matters of consumption. The lawsuit was filed at the United States District Court for the Northern District of California. “The final approval of the agreement has brought me a sense of justice,” said Pérez. “Knowing that those who were also affected are receiving part of this agreement give me the hope that they recognize that someone is defending them. I am incredibly grateful for all the support I received from Maldef to do this possible. He is inspiring and empowering to know that there are still people dedicated to helping our cause as immigrants. I will continue to fight against injustice and, with people like them by my side, I feel strength to continue fighting. ” Continue reading:• What documents should a foreigner carry in the United States before ICE raids?• Border tsar attack against Pope Francis for criticizing immigrants deportations• The White House spreads the first images of immigrants by addressing a plane to be deported (Tagstotranslate) Daca

US grants almost $600 million to Moderna to “accelerate” bird flu vaccine trials

The United States government has allocated a significant investment of almost $600 million to the biopharmaceutical company Moderna to accelerate the development of vaccines based on messenger RNA (mRNA) against avian flu, with special emphasis on flu strains that could become a pandemic threat. This financial support is part of the Department of Health and Human Services’ (HHS) ongoing efforts to anticipate and mitigate the risk of future public health crises, such as those caused by highly contagious and dangerous influenza viruses. Since 2023, Moderna has been working closely with the Biomedical Advanced Research and Development Authority (BARDA), an HHS entity, to develop mRNA vaccines. that can be used in the event that new strains of influenza emerge with the potential to become pandemics. This effort includes not only the research and development of vaccines against the H5N1 strain of bird flu, but also against other variants that could represent a danger to global health. In 2023, Moderna had already received $176 million as part of this initiative, and with the recent allocation of funds, the company will be able to accelerate its work and move more quickly toward creating an effective vaccine. One of Moderna’s key advances in this project is its mRNA-1018 vaccine, which is designed to combat the H5 and H7 bird flu viruses. This vaccine has demonstrated “positive preliminary data” in Phase 1 and 2 clinical trials, leading to optimism about its effectiveness in combating these dangerous strains. With additional funding provided by the US government, Moderna is in the preparation phase of launching a Phase 3 study of this vaccine, a crucial step towards its possible distribution in the event of a massive outbreak of bird flu. Face future threats The company intends to share findings from these trials at an upcoming medical conference, which could offer more insight into the vaccine’s potential to address future viral threats. The recent HHS funding will also allow Moderna to accelerate research and development of a vaccine against the H7N9 strain of bird flu, another variant that has concerned health authorities due to its ability to infect humans. Public health officials have noted that the speed with which new flu strains emerge and spread necessitates an innovative and flexible approach to vaccine development. In this regard, the US government’s financial support is designed to expand Moderna’s clinical trials, enabling the evaluation of multiple vaccines and increasing the database supporting the use of mRNA technology in these contexts. In addition to ongoing work with the H5N1 and H7N9 strains, HHS has expressed interest in having Moderna design up to four new vaccines against different flu strains that can be evaluated in Phase 1 studies. The goal of this initiative is to generate clinical data that supports the accelerated development of mRNA vaccines, that would be essential to contain future outbreaks of avian flu or any other influenza strain with pandemic potential. As flu viruses continue to mutate, the ability to quickly adapt to new variants will be key to preventing a global pandemic. Keep reading:

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.